GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biomarin Pharmaceutical Inc (NAS:BMRN) » Definitions » Selling, General, & Admin. Expense

Biomarin Pharmaceutical (Biomarin Pharmaceutical) Selling, General, & Admin. Expense

: $937 Mil (TTM As of Dec. 2023)
View and export this data going back to 1999. Start your Free Trial

Selling, general, & admin. expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. Biomarin Pharmaceutical's selling, general, & admin. expense for the three months ended in Dec. 2023 was $275 Mil. Its selling, general, & admin. expense for the trailing twelve months (TTM) ended in Dec. 2023 was $937 Mil.


Biomarin Pharmaceutical Selling, General, & Admin. Expense Historical Data

The historical data trend for Biomarin Pharmaceutical's Selling, General, & Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biomarin Pharmaceutical Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Selling, General, & Admin. Expense
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 680.90 737.70 759.40 854.00 937.30

Biomarin Pharmaceutical Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Selling, General, & Admin. Expense Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 245.70 223.00 215.34 224.00 275.00

Competitive Comparison

For the Biotechnology subindustry, Biomarin Pharmaceutical's Selling, General, & Admin. Expense, along with its competitors' market caps and Selling, General, & Admin. Expense data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biomarin Pharmaceutical Selling, General, & Admin. Expense Distribution

For the Biotechnology industry and Healthcare sector, Biomarin Pharmaceutical's Selling, General, & Admin. Expense distribution charts can be found below:

* The bar in red indicates where Biomarin Pharmaceutical's Selling, General, & Admin. Expense falls into.



Biomarin Pharmaceutical Selling, General, & Admin. Expense Calculation

Selling, General, & Admin. Expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. For instance, personnel cost, advertising, rent, communication costs are all part of SGA.

Selling, General, & Admin. Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $937 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biomarin Pharmaceutical  (NAS:BMRN) Selling, General, & Admin. Expense Explanation

An efficient operation keeps SGA costs low and thus has higher profit margin. The percentage of SGA relative to total revenue is an indication of how efficiently the company operates. Compare this percentage among the companies in the same industry is a good way of finding more efficient operations. A comparison of the SGA cost relative to the revenue with the historical value can also be an indication of how efficient the company has become.

Warren Buffett likes companies with consistent SGA as the percentage of gross profit.

Companies with no durable competitive advantage show wild variation in SG&A as % of Gross Profit.

If SGA is less than 30% of Gross Profit, it is fantastic. If SGA is nearing 100%, it is is in highly competitive industry.


Biomarin Pharmaceutical Selling, General, & Admin. Expense Related Terms

Thank you for viewing the detailed overview of Biomarin Pharmaceutical's Selling, General, & Admin. Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Biomarin Pharmaceutical (Biomarin Pharmaceutical) Business Description

Traded in Other Exchanges
Address
770 Lindaro Street, San Rafael, CA, USA, 94901
BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition to long-standing U.S. rights, BioMarin has reacquired international rights for Kuvan and Palynziq from Merck KGaA). Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) was approved in Europe in 2022 and in the U.S. in 2023.
Executives
Jean Jacques Bienaime director, officer: Chief Executive Officer 925 PAGE MILL ROAD, PALO ALTO CA 94304
George Eric Davis officer: VP, General Counsel C/O BIOMARIN PHARMACEUTICAL INC., 105 DIGITAL DRIVE, NOVATO CA 94949
Jeffrey Robert Ajer officer: EVP, Chief Commercial Officer C/O BIOMARIN PHARMACEUTICAL INC., 105 DIGITAL DRIVE, NOVATO CA 94949
Henry J Fuchs officer: Chief Medical Officer C/O BIOMARIN PHARMACEUTICAL INC., 105 DIGITAL DRIVE, NOVATO CA 94949
Charles Greg Guyer officer: EVP, Chief Technical Officer C/O BIOMARIN PHARMACEUTICAL INC., 770 LINDARO ST., SAN RAFAEL CA 94901
Brian Mueller officer: EVP, Chief Financial Officer C/O BIOMARIN PHARMACEUTICAL INC., 105 DIGITAL DRIVE, NOVATO CA 94949
Mark J Alles director C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901
Elizabeth M Anderson director 10 FINDERNE AVENUE, BUILDING 10, BRIDGEWATER NJ 08807
Maykin Ho director C/O AGIOS PHARMACEUTICALS, INC., 88 SIDNEY STREET, CAMBRIDGE MA 02139
Erin Burkhart officer: GVP, Chief Accounting Officer C/O BIOMARIN PHARMACEUTICAL INC., 770 LINDARO ST., SAN RAFAEL CA 94901
V Bryan Lawlis director
Richard A Meier director C/O INTERSECT ENT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025
Dennis Slamon director 770 LINDARO STREET, SAN RAFAEL CA 94901
Michael G Grey director C/O SGX PHARMACEUTICALS, INC., 10505 ROSELLE STREET, SAN DIEGO CA 92121
Pyott David E I director C/O ALLERGAN, 2525 DUPONT DRIVE, IRVINE CA 92612

Biomarin Pharmaceutical (Biomarin Pharmaceutical) Headlines

From GuruFocus